GLP-1 is creating a new market for nutraceutical brands: products designed around the changing nutrition priorities of people using these therapies. GLP-1 supplements are not substitutes for GLP-1 drugs; the opportunity is in companion nutrition formats such as protein, micronutrients, fiber, and probiotics.
GLP-1 stands for glucagon-like peptide-1, a hormone involved in appetite and glucose regulation. The rapid adoption of GLP-1 medications such as Ozempic and Wegovy is also influencing adjacent nutrition and supplement categories.
GLP-1 Drugs are Reshaping the Supplement Market
The opportunity is not to replicate GLP-1 medications. It is to formulate around nutrition priorities emerging alongside their use.
The global GLP-1 receptor agonist market was valued at $66.4 billion in 2025 and is projected to reach $185.3 billion by 2033. The weight-loss supplement market is separately projected to reach $71.6 billion by 2030.
The supplement market is already moving beyond traditional weight-management products. As GLP-1 adoption grows, brands are exploring companion nutrition concepts centered on protein intake, micronutrients, digestive health, and other nutritional priorities associated with reduced food intake.
GLP-1 Supplements are Moving Toward Nutrition Support
Lower food intake can increase the focus on nutrient density, while weight loss can include reductions in fat-free mass. For brands, this creates white space around everyday nutrition support without making drug-like claims. Clinical research on newer GLP-1 receptor agonists has documented reductions in fat mass alongside more modest reductions in fat-free mass.
Key formulation areas include:
- Protein and amino-acid products positioned around adequate protein intake.
- Multivitamin and mineral formulas designed for nutrient-density needs.
- Fiber products for everyday digestive nutrition.
- Probiotic and prebiotic formulas aligned with continued interest in gut health.
- Hydration and electrolyte products for broader daily nutrition routines.
The strongest opportunity for nutraceutical brands lies in clearly defined companion nutrition concepts, not products positioned as alternatives to GLP-1 medications. Formulation, positioning, and claims should remain focused on specific nutritional needs and the requirements of the intended market.
Capsule Format Matters for GLP-1 Products
For capsule-based companion formulas, shell selection should follow the formulation, target consumer, and brand positioning, not the GLP-1 trend itself.
Lyfe Group’s empty capsules include vegetarian capsules made from HPMC and gelatin capsules. K-CAPS® HPMC capsules are plant-derived and suitable for a wide range of formulations, including moisture-sensitive fills. G-CAPS® are made from 100% bovine hide gelatin and can be customized through color, finish, and printing.
Brands developing GLP-1 capsules or other companion formats should evaluate:
- fill-material compatibility;
- moisture sensitivity;
- capsule size and fill capacity;
- dietary positioning;
- color, printing, and finish requirements;
- filling-machine performance.
For additional guidance, see choosing between gelatin and vegetarian capsules and our gelatin capsule details.
Empty Capsules Support GLP-1 Companion Product Development
For brands entering this emerging category, early formulation decisions can help translate a defined nutritional need into the right dosage format.
At Lyfe Group, we support nutraceutical brands developing companion nutrition products with capsule solutions designed for different formulation and positioning needs. Our portfolio includes vegetarian HPMC capsules and gelatin capsules, with options across sizes, colors, printing, and other customization requirements.
For brands evaluating opportunities around the GLP-1 market, the priority should be to define the nutritional need, formulation requirements, target consumer, and dosage format before moving into product development.
Ready to evaluate capsule options for a companion formulation? Talk to our team or request a quote.
